瑞舒伐他汀与阿托伐他汀对经皮冠状动脉介入治疗患者术后血浆白介素-18浓度的影响  

Comparison of effect of rosuvastatin versus atorvastatin treatment on systemic concentrations of IL-18 in patients treated by percutaneous coronary intervention

作　　者：汪蓓蕾[1] 华锦胜[1] 胡章乐[1] 陈鸿武[1] 马礼坤[1] 

机构地区：[1]安徽医科大学附属省立医院安徽省立医院心内科,合肥230001

出　　处：《中国临床保健杂志》2015年第6期615-617,共3页Chinese Journal of Clinical Healthcare

摘　　要：目的 研究他汀类药物对行经皮冠状动脉介入治疗（PCI）患者血浆白介素18（IL-18）的影响,比较两种不同他汀上述效应的差异。方法 选取116例不稳定型心绞痛患者,采用简单随机抽样法分为瑞舒伐他汀（10 mg/d）组和阿托伐他汀治疗（20 mg/d）组并于入院后48-72 h接受PCI处理。分别测定两组PCI前后不同时间静脉中IL-18水平并进行比较分析。结果 PCI术后24 h,两组IL-18浓度均明显升高;PCI术后72 h,两组IL-18浓度均又明显降低;PCI术后24 h及术后72 h,瑞舒伐他汀组IL-18浓度均显著低于阿托伐他汀组。结论他汀类药物能显著降低PCI术后循环中的IL-18浓度;与阿托伐他汀20 mg/d相比,瑞舒伐他汀10 mg/d的效应更强而可能具有更好的保护作用。Objective To explore effects of statin treatment on plasma intedeukin 18 （IL-18）level in patients treated by percutaneous coronary intervention （PCI） and compare the difference between rosuvastatin and atorvastatin. Methods A total of 116 patients with unstable angina pectoris were enrolled and randomized to rosuvastatin 10mg/d or atorvastatin 20 rag/day once daily for 7 days. All patients underwent PCI at the timing of 48-72 hours after their admission. Plasma samples were collected on admission, before and 24 hours ,72 hours after PCI in all the patients respectively to measure IL-18 levels. Results Before PCI,plasma IL-18 levels fell significantly from the admission in both groups. After PCI,IL-18 concentrations markedly increased at 24 hours and then significantly dropped at 72 hours in both groups. There was no difference in clinical characteristics, admission IL-18 levels and IL-18 levels before PCI between the two groups. However,the plasm IL-18 levels in the rosuvastatin group was lower than that in the atorvastatin group at 24 hours and 72 hours after PCI. Conclusion Rosuvastatin （ 10 mg/d） shows stronger effect on IL-18 inhibition than atorvastatin （20 mg/d） in patients who underwent PCI.

关 键 词：心绞痛 不稳定型 心肌血管重建术 白细胞介素18 羟甲基戊二酰基Co A还原酶抑制剂 

分 类 号：R541.4[医药卫生—心血管疾病]